Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on HR20031 Tablet in Healthy Subjects
NCT05692934Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR20031 FDC in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Curve to the Last Quantifiable Concentration at Day 8 and 1 more. Started Jan 2023; status: completed.
02
Drugs
HR20031 FDC
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05692934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692934.